Zydus Cadila gets US FDA nod to market osteoporosis, ortho treatment drug

MUMBAI | AHMEDABAD | RAJKOT – Dr Pankaj Patel led and Ahmedabad headquartered Zydus Cadila Group (Cadila Healthcare Ltd) has received final approval from the US regulators to market ortho treatment medicine, the company said in a press release submitted to the Indian Bourses, today.

Zydus Cadila has received the final approval from the USFDA to market Risedronate Sodium Delayed-Release Tablets (US RLD — ATELVIA® delayed-release tablets), 35 mg.

It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

Risedronate is a medicine of bisphosphonate group that alters bone formation and breakdown in the body.

This can slow bone loss and may help prevent bone fractures.

This medicine is used to treat osteoporosis in women, caused by menopause.

The group now has 218 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.


Follow DATELINE GUJARAT On :-

FacebookGoogle+LinkedinTwitterYouTube 


SHARE THIS NEWS ON :-